169 related articles for article (PubMed ID: 19996602)
1. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
3. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
4. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
5. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
6. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial comparing GnRH antagonist cetrorelix with GnRH agonist leuprorelin for endometrial thinning prior to transcervical resection of endometrium.
Bhatia K; Doonan Y; Giannakou A; Bentick B
BJOG; 2008 Sep; 115(10):1214-24. PubMed ID: 18715405
[TBL] [Abstract][Full Text] [Related]
8. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
10. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study.
Cirkel U; Ochs H; Schneider HP; Mettler L; Mayer-Eichberger D; Schindler AE; Bühler K; Winkler U; Zahradnik HP; Künzig HJ
Clin Ther; 1992; 14 Suppl A():37-50. PubMed ID: 1606593
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial.
Serra GB; Panetta V; Colosimo M; Romanini C; Lafuenti GB; Garcea N; Votano S; Agatensi L
Clin Ther; 1992; 14 Suppl A():57-73. PubMed ID: 1606594
[TBL] [Abstract][Full Text] [Related]
13. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
14. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
[TBL] [Abstract][Full Text] [Related]
15. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate.
Shozu M; Sumitani H; Segawa T; Yang HJ; Murakami K; Inoue M
J Clin Endocrinol Metab; 2001 Nov; 86(11):5405-11. PubMed ID: 11701714
[TBL] [Abstract][Full Text] [Related]
17. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
19. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
20. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
